Laajala, Teemu Daniel

Susceptibility of low-density lipoprotein particles to aggregate depends on particle lipidome, is modifiable, and associates with future cardiovascular deaths

Ruuth, M., Nguyen, S. D., Vihervaara, T., Hilvo, M., Laajala, T. D., Kondadi, P. K., Gisterå, A., Lähteenmäki, H., Kittilä, T., Huusko, J., et al. (2018) · European Heart Journal

Lipoproteins and Cardiovascular HealthAtherosclerosis and Cardiovascular Diseases

Cited by 180

PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells

Kauko, O., O’Connor, C. M., Kulesskiy, E., Sangodkar, J., Aakula, A., Izadmehr, S., Yetukuri, L., Yadav, B., Padzik, A., Laajala, T. D., et al. (2018) · Science Translational Medicine

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 149

Phosphoproteome and drug-response effects mediated by the three protein phosphatase 2A inhibitor proteins CIP2A, SET, and PME-1

Kauko, O., Imanishi, S. Y., Kulesskiy, E., Yetukuri, L., Laajala, T. D., Sharma, M., Pavic, K., Aakula, A., Rupp, C., Jumppanen, M., et al. (2020) · Journal of Biological Chemistry

Protein Tyrosine PhosphatasesProtein Kinase Regulation and GTPase Signaling

Cited by 65

Label-free quantitative phosphoproteomics with novel pairwise abundance normalization reveals synergistic RAS and CIP2A signaling

Kauko, O., Laajala, T. D., Jumppanen, M., Hintsanen, P., Suni, V., Haapaniemi, P., Corthals, G., Aittokallio, T., Westermarck, J., & Imanishi, S. Y. (2015) · Scientific Reports

Advanced Proteomics Techniques and ApplicationsProtein Kinase Regulation and GTPase Signaling

Cited by 61

Optimized design and analysis of preclinical intervention studies in vivo

Laajala, T. D., Jumppanen, M., Huhtaniemi, R., Fey, V., Kaur, A., Knuuttila, M., Aho, E., Oksala, R., Westermarck, J., Mäkelä, S., et al. (2016) · Scientific Reports

Statistical Methods in Clinical TrialsAnimal testing and alternatives

Cited by 48

CIP2A promotes T-cell activation and immune response to Listeria monocytogenes infection

Côme, C., Cvrljevic, A., Khan, M. M., Treise, I., Adler, T., Aguilar-Pimentel, J. A., Au-Yeung, B., Sittig, E., Laajala, T. D., Chen, Y., et al. (2016) · PLoS ONE

T-cell and B-cell ImmunologySignaling Pathways in Disease

Cited by 20

Cost-effective survival prediction for patients with advanced prostate cancer using clinical trial and real-world hospital registry datasets

Murtojärvi, M., Halkola, A. S., Airola, A., Laajala, T. D., Mirtti, T., Aittokallio, T., & Pahikkala, T. (2020) · International Journal of Medical Informatics

Statistical Methods and InferenceRadiomics and Machine Learning in Medical Imaging

Cited by 14

Ovarian Cancers with Low CIP2A Tumor Expression Constitute an APR-246–Sensitive Disease Subtype

Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Butzow, R., Haglund, C., Kaipio, K., Arsiola, T., et al. (2022) · Molecular Cancer Therapeutics

Ovarian cancer diagnosis and treatmentCancer Mechanisms and Therapy

Cited by 5

Ovarian cancers with low CIP2A tumor expression constitute an APR-246 sensitive disease subtype

Cvrljevic, A. N., Butt, U., Huhtinen, K., Grönroos, T. J., Böckelman, C., Lassus, H., Kaipio, K., Arsiola, T., Laajala, T. D., Connolly, D. C., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory)

Ovarian cancer diagnosis and treatmentCancer Mechanisms and Therapy

Cited by 5